Wednesday, 18 November 2026European Markets

ULTIMOVACS Stock Went Down By Over 31% So Far On Thursday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of ULTIMOVACS (Oslo Børs Benchmark Index_GI: ULTI.OL) slid by a staggering 31.62% to kr80.00 at 11:37 EST on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.22% to kr1,230.30, following the last session's upward trend. This seems, up until now, a somewhat bullish trend exchanging session today.

ULTIMOVACS's last close was kr117.00, 17.95% below its 52-week high of kr142.60.

About ULTIMOVACS

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-4.57.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -33.74%.

Yearly Top and Bottom Value

ULTIMOVACS's stock is valued at kr80.00 at 11:37 EST, way under its 52-week high of kr142.60 and way above its 52-week low of kr58.50.

Volatility

ULTIMOVACS's last week, last month's, and last quarter's current intraday variation average was a negative 1.11%, a negative 0.43%, and a positive 1.90%.

ULTIMOVACS's highest amplitude of average volatility was 1.70% (last week), 1.57% (last month), and 1.90% (last quarter).

Moving Average

ULTIMOVACS's worth is way under its 50-day moving average of kr121.26 and way below its 200-day moving average of kr101.44.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ULTIMOVACS's stock is considered to be overbought (>=80).

More news about ULTIMOVACS (ULTI.OL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 8 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›